3-(4-chlorophenyl)-glutaric acid monoethyl ester | 860011-99-0

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 苯丙酸
• 英文名称: 3-(4-chlorophenyl)-glutaric acid monoethyl ester
• 英文别名: 3-(4-chlorophenyl)glutaric acid monoethyl ester；3-(4-Chloro-phenyl)-pentanedioic acid monoethyl ester；3-(4-chlorophenyl)-5-ethoxy-5-oxopentanoic acid
• CAS: 860011-99-0
• 化学式: C₁₃H₁₅ClO₄
• 分子量: 270.713
• InChiKey: UHJGINMAWCPVIA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  63.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(4-chlorophenyl)-glutaric acid monoethyl ester 在 草酰氯 作用下， 以 四氢呋喃 、 二氯甲烷 为溶剂， 生成
  参考文献：
  名称：

  Synthesis of 2,5-thiazole butanoic acids as potent and selective αvβ3 integrin receptor antagonists with improved oral pharmacokinetic properties

  摘要：

  We describe a series of 2,5 thiazole containing compounds, which are potent antagonists of the integrin alpha(V)beta(3) and show selectivity relative to the other integrins, such as alpha(IIB)beta(3) and alpha(V)beta(6). These analogs were demonstrated to have high bioavailability relative to other relative heterocyclic analogs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.017
• 作为产物：
  描述：

  4-氯苯甲醛 在 哌啶 、 乙酸酐 作用下， 生成 3-(4-chlorophenyl)-glutaric acid monoethyl ester
  参考文献：
  名称：

  Synthesis of 2,5-thiazole butanoic acids as potent and selective αvβ3 integrin receptor antagonists with improved oral pharmacokinetic properties

  摘要：

  We describe a series of 2,5 thiazole containing compounds, which are potent antagonists of the integrin alpha(V)beta(3) and show selectivity relative to the other integrins, such as alpha(IIB)beta(3) and alpha(V)beta(6). These analogs were demonstrated to have high bioavailability relative to other relative heterocyclic analogs. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.11.017

文献信息

• AMINOTETRALIN COMPOUNDS AS MU OPIOID RECEPTOR ANTAGONISTS
  申请人：Leadbetter Michael R.

  公开号：US20090149465A1

  公开（公告）日：2009-06-11

  The invention provides aminotetralin compounds of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

  该发明提供了公式（I）的氨基四氯化合物：其中R1、R2、R3、R4、R5、R6、R7、n和m在规范中定义，或其药用可接受盐，这些化合物是μ阿片受体的拮抗剂。该发明还提供了包含这种化合物的药物组合物，使用这种化合物治疗与μ阿片受体活性相关的疾病的方法，以及用于制备这种化合物的过程和中间体。
• PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 3-SUBSTITUTED GLUTARIC ACID MONOAMIDE
  申请人：Kaneka Corporation

  公开号：EP2518050A1

  公开（公告）日：2012-10-31

  The process for producing an optically active 3-substituted glutaric acid monoamide is characterized in comprising the step of precipitating the optically active 3-substituted glutaric acid monoamide by mixing an acid and a mixed liquid containing an optically active 3-substituted glutaric acid monoamide represented by the following formula (2): wherein * indicates an asymmetric carbon atom; R1 is a C1-8 alkyl group, a C2-8 alkenyl group, a C2-8 alkynyl group, a C4-20 aryl group or a C5-20 aralkyl group; and the alkyl group, the alkenyl group, the alkynyl group, the aryl group and the aralkyl group may have a substituent, a basic compound, water and an organic solvent.

  生产光学活性的3-取代戊二酸单酰胺的过程的特点在于包括通过混合含有下列式(2)所表示的光学活性的3-取代戊二酸单酰胺的混合液和酸来沉淀光学活性的3-取代戊二酸单酰胺的步骤：其中*表示不对称碳原子；R1是C1-8烷基、C2-8烯基、C2-8炔基、C4-20芳基或C5-20芳基烷基；烷基、烯基、炔基、芳基和芳基烷基可能有取代基，碱性化合物，水和有机溶剂。
• Aminotetralin compounds as mu opioid receptor antagonists
  申请人：Theravance, Inc.

  公开号：US08101791B2

  公开（公告）日：2012-01-24

  The invention provides aminotetralin compounds of formula (I): wherein R1, R2, R3, R4, R5, R6, R7, n, and m are defined in the specification, or a pharmaceutically-acceptable salt thereof, that are antagonists at the mu opioid receptor. The invention also provides pharmaceutical compositions comprising such compounds, methods of using such compounds to treat conditions associated with mu opioid receptor activity, and processes and intermediates useful for preparing such compounds.

  本发明提供式(I)的氨基四氢萘化合物：其中R1、R2、R3、R4、R5、R6、R7、n和m在说明书中有定义，或其药学上可接受的盐，它们是μ阿片受体拮抗剂。本发明还提供包括这样的化合物的制药组合物，使用这样的化合物治疗与μ阿片受体活性相关的疾病的方法，以及用于制备这样的化合物的过程和中间体。
• Enzymatic desymmetrization of 3-arylglutaric acid anhydrides
  作者：Anna Fryszkowska、Marta Komar、Dominik Koszelewski、Ryszard Ostaszewski

  DOI：10.1016/j.tetasy.2005.06.025

  日期：2005.7

  Optically active (R)- and (S)-3-arylglutaric acid monoesters 3 were synthesized in quantitative yields and good stereoselectivities by lipase-catalyzed desymmetrization of the corresponding 3-arylglutaric anhydrides 2 with alcohols. It was observed that the stereochemical outcome of the reaction was influenced by the substituents present on the aromatic ring. The influence of the enzyme, alcohol, and solvent was systematically examined. Absolute configurations of the monoesters 3 were assigned by chemical correlation to corresponding lactones 4. (C) 2005 Elsevier Ltd. All rights reserved.
• One-pot enzymatic desymmetrization and Ugi MCR
  作者：Anna Fryszkowska、Jadwiga Frelek、Ryszard Ostaszewski

  DOI：10.1016/j.tet.2005.04.032

  日期：2005.6

  A new approach to the synthesis of chiral peptidomimetics is reported. It combines an enzymatic desymmetrization of 3-phenylglutaric anhydrides with a subsequent Ugi multi-component reaction in a one-pot, two-step procedure. NMR and CD spectroscopy was used to assign the configurations of obtained products. Our synthetic method is very efficient and it can easily be extended to other types of multi-component reactions and can be used for the preparation of chiral peptidomimetic libraries. (c) 2005 Elsevier Ltd. All rights reserved.